Dexcom reports 2Q 2021 financial results

DexCom, Inc. today reported its financial results as of and for the quarter ended September 30, 2021.

Third Quarter 2021 Financial Highlights:

• Revenue grew 30% versus the same quarter of the prior year to $650.2 million on a reported basis and 28% on an organic1 basis.
• U.S. revenue growth of 23% and international revenue growth of 57% on a reported basis. International growth was 46% on an organic1 basis.
• GAAP operating income of $118.3 million or 18.2% of revenue, a decrease of 60 basis points compared to the third quarter of 2020. Non-GAAP operating income* of $123.8 million or 19.0% of revenue, in line with the same quarter of the prior year.

Strategic Highlights:

• Received FDA clearance for two key software solutions that enhance Dexcom’s connected ecosystem
• Completed the acquisition of our distributor in Australia and New Zealand, advancing Dexcom’s strategy to transition certain international markets from distributors to direct sales.
• Introduced a new product with the launch of Dexcom ONE, a key addition to our portfolio as we seek to broaden access to healthcare for people with diabetes globally.

“In the third quarter Dexcom continued to progress toward our goal of broadening access and advancing our leadership position in CGM-driven connected solutions and customer choice,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “We are pleased to once again be in a position to raise our full-year revenue and margin guidance as we drive toward a strong conclusion of 2021 and the upcoming launch of our Dexcom G7 system.” Business Wire